Max Chat
Company Analysis Apeloa Pharmaceutical Co.,Ltd
1. Summary
Advantages
- The stock's return over the last year (-11.49%) is higher than the sector average (-33.02%).
- Current debt level 0% is below 100% and has decreased over 5 years from 1.87%.
- The company's current efficiency (ROE=19.9%) is higher than the sector average (ROE=11.95%)
Disadvantages
- Price (14.72 Β₯) is higher than fair price (12.12 Β₯)
- Dividends (1.68%) are below the sector average (1.83%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Apeloa Pharmaceutical Co.,Ltd | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.1% | 0% | 4.7% |
| 90 days | 1% | -12% | 3.2% |
| 1 year | -11.5% | -33% | 37.3% |
000739 vs Sector: Apeloa Pharmaceutical Co.,Ltd has outperformed the "Healthcare" sector by 21.53% over the past year.
000739 vs Market: Apeloa Pharmaceutical Co.,Ltd has significantly underperformed the market by -48.79% over the past year.
Stable price: 000739 is not significantly more volatile than the rest of the market on "Shenzhen Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 000739 with weekly volatility of -0.2209% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (14.72 Β₯) is higher than the fair price (12.12 Β₯).
Price is higher than fair: The current price (14.72 Β₯) is 17.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (19.22) is lower than that of the sector as a whole (69.4).
P/E vs Market: The company's P/E (19.22) is lower than that of the market as a whole (63.57).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.62) is lower than that of the sector as a whole (3.96).
P/BV vs Market: The company's P/BV (3.62) is lower than that of the market as a whole (3.79).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.79) is lower than that of the sector as a whole (6.51).
P/S vs Market: The company's P/S indicator (1.79) is lower than that of the market as a whole (5.87).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.26) is higher than that of the sector as a whole (11.85).
EV/Ebitda vs Market: The company's EV/Ebitda (15.26) is lower than that of the market as a whole (25.54).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 6.45% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (6.45%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (19.9%) is higher than that of the sector as a whole (11.95%).
ROE vs Market: The company's ROE (19.9%) is higher than that of the market as a whole (9.38%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (5.4%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (3.95%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.68% is below the average for the sector '1.83%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.68% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 1.68% has been growing over the last 5 years. Growth over 5 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (31.04%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
